title: Pregnancy outcome after cabergoline treatment in early weeks of gestation.
abstract: We collected information on 61 pregnancies in 50 women treated with cabergoline. These pregnancies resulted in 12 (19.7%) early terminations (five induced abortions, six spontaneous abortions, one hydatidiform mole) and 49 (80.3%) live births. In one case, malformations were suspected by a gynecologist based on ultrasound at 12 gestational weeks and the pregnancy was terminated; additional information was not available. There was one case of trisomy 18. The frequency of spontaneous and induced abortions and major congenital malformations was comparable with rates in the general population. The data did not indicate any potential adverse effect of the drug on pregnancy. The data from this study in combination with previous reports can exclude a congenital malformation risk greater than 10% associated with pregnancy exposure to cabergoline.
authors.affiliation: Istituto di Ricerche Farmacologiche "Mario Negri", Via Eritrea 62-20157, Milan, Italy. ricci@marionegri.it
authors.forename: Elena
authors.initials: E
authors.lastname: Ricci
authors.forename: Fabio
authors.initials: F
authors.lastname: Parazzini
authors.forename: Tiziano
authors.initials: T
authors.lastname: Motta
authors.forename: Carlo I
authors.initials: CI
authors.lastname: Ferrari
authors.forename: Annamaria
authors.initials: A
authors.lastname: Colao
authors.forename: Antonio
authors.initials: A
authors.lastname: Clavenna
authors.forename: Francesca
authors.initials: F
authors.lastname: Rocchi
authors.forename: Emanuela
authors.initials: E
authors.lastname: Gangi
authors.forename: Sandra
authors.initials: S
authors.lastname: Paracchi
authors.forename: Maurizio
authors.initials: M
authors.lastname: Gasperi
authors.forename: Maurizio
authors.initials: M
authors.lastname: Lavezzari
authors.forename: Anna Elisa
authors.initials: AE
authors.lastname: Nicolosi
authors.forename: Simona
authors.initials: S
authors.lastname: Ferrero
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Landi
authors.forename: Paolo
authors.initials: P
authors.lastname: Beck-Peccoz
authors.forename: Maurizio
authors.initials: M
authors.lastname: Bonati
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000453:epidemiology / Q000209:etiology; D000022:Abortion, Spontaneous / Q000453:epidemiology; D000328:Adult; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005865:Gestational Age; D006801:Humans; D007558:Italy / Q000453:epidemiology; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline